PKN3 and pancreatic neoplasm: An siRNA drug called Atu027 silenced the expression of a pro-metastatic ligand termed protein kinase N3 (PKN3) in endothelial cells and induced dramatic regression of distant metastasis of pancreatic cancer in phase I and II clinical trials [263, 264].